

Scientific Program


2nd **BARCELONA**

INTERNATIONAL WORKSHOP ON

CLINICAL TRIALS IN MASH cACLD/CIRRHOSIS

26th of May 2026

BARCELONA



Liver Unit




Liver Diseases Group

DIRECTORS

Dr. Joan Genescà, Clinical Director of Digestive Diseases and Chief of Liver Unit, Vall d'Hebron University Hospital; Professor of Medicine, Universitat Autònoma de Barcelona; CIBERehd, Institute of Health Carlos III.

Dr. Juan M Pericàs, Consultant at Liver Unit, Vall d'Hebron University Hospital; Universitat Autònoma de Barcelona; CIBERehd, Institute of Health Carlos III.



OBJECTIVES

Review **patient selection criteria** and **endpoints** in clinical trials in patients with MASH cACLD/cirrhosis

VENUE

Hotel Porta Fira
Plaza Europa, 45
L'Hospitalet de Llobregat, Barcelona, Spain (Near EASL Congress venue)

REGISTRATION

Free of charge
Registrations must be made through the following website:
<https://www.vallhebron.com/en/teaching/aula-vall-dhebron/scientific-agenda>

Special dietary requirements must be notified to the Technical Secretary during the registration process (inscripciones@aulavallhebron.cat).

TECHNICAL SECRETARY



Aula Vall d'Hebron - External Training Activities
inscripciones@aulavallhebron.cat
+34 693 785 436

SPEAKERS & MODERATORS



ALEKSANDER KRAG

Professor of Hepatology
Odense University Hospital, Odense (Denmark)

ANNALISA BERZIGOTTI

Head of Hepatology
a.i. Clinic Director
Department of Visceral Surgery and Medicine
Inselspital, Bern University Hospital (Switzerland)

ARUN SANYAL

Professor of Medicine
Director, Stravitz-Sanyal Institute for Liver Disease and Metabolic Health
Virginia Commonwealth University, Richmond, VA (USA)

EMMANUEL TSOCHATZIS

Professor of Hepatology
UCL Institute for Liver and Digestive Health
Royal Free Hospital and UCL, London (United Kingdom)

FRANK TACKE

Professor of Hepatology
Head, Department of Hepatology and Gastroenterology
Charité – Universitätsmedizin Berlin (Germany)

JOAN GENESCÀ

Professor of Medicine
Clinical Director of Digestive Diseases and Head of Hepatology
Vall d'Hebron University Hospital, Barcelona
CIBERehd – Instituto de Salud Carlos III (Spain)

JUAN G. ABRALDES

Professor of Medicine – Division of Gastroenterology
University of Alberta, Edmonton (Canada)

JUAN M. PERICÀS

Consultant, Liver Unit
Vall d'Hebron University Hospital, Barcelona
CIBERehd – Instituto de Salud Carlos III (Spain)

LAURENT CASTERA

Professor of Hepatology
Hôpital Beaujon, Clichy (France)

MANUEL ROMERO-GÓMEZ

Professor of Medicine
Hospital Universitario Virgen del Rocío, Seville
CIBERehd – Instituto de Salud Carlos III (Spain)

MAZEN NOUREDDIN

Professor of Medicine
Houston Methodist Hospital and Houston Research Institute
Houston, TX (USA)

QUENTIN M. ANSTEE

Professor of Experimental Hepatology
Newcastle University, Newcastle (United Kingdom)

RAFAEL BAÑARES

Professor of Medicine
Complutense University of Madrid
Consultant, Digestive Medicine Department
Hospital Universitario Gregorio Marañón, Madrid
CIBERehd – Instituto de Salud Carlos III (Spain)

SVEN FRANCKE

Professor of Medicine
Chairman, Division of Gastroenterology and Hepatology
Antwerp University Hospital, University of Antwerp (Belgium)


VINCENT WONG

Professor of Medicine
Chinese University of Hong Kong, Hong Kong (China)

VLAD RATZIU

Professor of Hepatology
Institute for Cardiometabolism and Nutrition (ICAN)
Hôpital Pitié-Salpêtrière, Paris (France)

PROGRAM



16.00 - 16.10 pm | Welcome: Dr. Joan Genescà & Dr. Rafael Bañares

16.10 - 17.30 pm | Roundtable 1: MASH cACLD/cirrhosis clinical trials: patient selection

Moderators: Laurent Castera & Manuel Romero-Gómez

1. **Are we going to treat MASH cACLD or cirrhosis?** (15 min) – **E. Tsochatzis**
 2. **Patient selection: still with liver biopsy?** (15 min) – **Q. M. Anstee**
 3. **Patient selection: with NITs/models?** (15 min) – **J. G. Abraldes**
 4. **Will MetALD trials in cirrhotics be different?** (15 min) – **A. Krag**
- Discussion** (20 min)

17.30 - 17.50 pm | Coffee break

17.50 - 19.10 pm | Roundtable 2: MASH cACLD/cirrhosis clinical trials: endpoints

Moderators: Annalisa Berzigotti & Vincent Wong

1. **Endpoints: liver biopsy still needed?** (15 min) - **S. Francque**
 2. **Endpoints: with NITs/models?** (15 min) - **M. Noureddin**
 3. **Clinical endpoints.** (15 min) – **A. Sanyal**
 4. **Therapies for MASH cACLD/cirrhosis: monotherapy or combined?** (15 min) - **V. Ratziu**
- Discussion** (20 min)

19.10-19.20 pm | Closing: Dr. Juan M Pericàs & Dr. Frank Tacke

19.20-20.00 pm | Farewell Buffet

SPONSORS



For the **2nd Barcelona International Workshop on Clinical Trials in MASH cACLD/cirrhosis**, we would like to express our sincere appreciation to all **scientific and industry sponsors** for their invaluable support.

Their commitment has been essential in making this workshop possible and in fostering progress in research, collaboration, and clinical innovation in hepatology.

We are truly grateful for their continued trust and partnership.

SCIENTIFIC



INDUSTRY

SAPPHIRE SPONSORSHIP



PLATINUM SPONSORSHIP



BRONZE SPONSORSHIP




OTHER SPONSORSHIP



2nd **BARCELONA**

INTERNATIONAL WORKSHOP ON

CLINICAL TRIALS IN MASH cACLD/CIRRHOSIS



Liver Unit



Liver Diseases Group